Novo Nordisk's hemophilia drug shows potential as once-monthly treatment
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13970464.ece/ALTERNATES/schema-16_9/20140108-043159-pf-1600x898we.jpg)
Novo Nordisk’s hemophilia drug, Mim8, has ”demonstrated potential as a once-monthly treatment” for hemophilia A, the company reported in a Monday press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.